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INTRODUCTION
Breast cancer is the most common type of 
malignancy and one of the leading causes of death 
among women worldwide. Susceptibility to the disease 
is heavily influenced by inherited factors, with roughly 
50% of familial breast cancer risk attributable to genetic 
variation [1, 2]. Genetic variation also contributes to 
the phenotypic spectrum of the disease, with both high-
penetrance and common variants associating with various 
histopathological features, most notably estrogen receptor 
status [3].
The impact of genetic variation on breast cancer 
prognosis is less well understood. The prognosis and 
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ABSTRACT
We have utilized a two-stage study design to search for SNPs associated with 
the survival of breast cancer patients treated with adjuvant chemotherapy. Our 
initial GWS data set consisted of 805 Finnish breast cancer cases (360 treated with 
adjuvant chemotherapy). The top 39 SNPs from this stage were analyzed in three 
independent data sets: iCOGS (n=6720 chemotherapy-treated cases), SUCCESS-A 
(n=3596), and POSH (n=518). Two SNPs were successfully validated: rs6500843 (any 
chemotherapy; per-allele HR 1.16, 95% C.I. 1.08-1.26, p=0.0001, p(adjusted)=0.0091), 
and rs11155012 (anthracycline therapy; per-allele HR 1.21, 95% C.I. 1.08-1.35, 
p=0.0010, p(adjusted)=0.0270). The SNP rs6500843 was found to specifically interact 
with adjuvant chemotherapy, independently of standard prognostic markers 
(p(interaction)=0.0009), with the rs6500843-GG genotype corresponding to the highest 
hazard among chemotherapy-treated cases (HR 1.47, 95% C.I. 1.20-1.80). Upon 
trans-eQTL analysis of public microarray data, the rs6500843 locus was found to 
associate with the expression of a group of genes involved in cell cycle control, 
notably AURKA, the expression of which also exhibited differential prognostic value 
between chemotherapy-treated and untreated cases in our analysis of microarray 
data. Based on previously published information, we propose that the eQTL genes 
may be connected to the rs6500843 locus via a RBFOX1-FOXM1 -mediated regulatory 
pathway.
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indicated treatment for breast cancer is influenced by tumor 
grade, stage, HER2 expression, and hormone receptor 
status [4, 5], and it is plausible that genetic variants 
associated with these features would be of prognostic 
and predictive interest. Additionally, genetic variation 
may contribute to breast cancer survival independently of 
these markers, potentially by affecting the efficacy of the 
treatment. For example, prognostic and predictive SNPs 
have been reported in the TP53 gene and its regulatory 
network, as well as in genes involved in oxidative stress 
[6-10]. Such findings have emerged primarily from 
candidate gene based approaches, as more comprehensive 
GWS-based survival analyses tend to be problematic due 
to issues of statistical power: very large sample sizes are 
required to reach GWS significance. The collaborative 
iCOGS genotyping project [2] now enables this type of 
a study, with over 30,000 genotyped breast cancer cases 
eligible for survival analysis, of which 17828 cases have 
adjuvant treatment information available, although it can 
still be challenging to detect modest effect sizes in smaller 
subgroups, such as genetic effects that modulate survival 
after a specific type of adjuvant treatment.
We have utilized a two-stage study design to search 
for genetic variants associated with survival after adjuvant 
chemotherapy in breast cancer. First, we conducted an 
initial pilot GWS in an event-enriched set of 805 Finnish 
breast cancer cases. We then sought to validate our 
findings in an independent validation material consisting 
of three separate studies: iCOGS [2], POSH [11], and 
SUCCESS-A (dbGaP Study Accession: phs000547.v1.p1). 
SNPs associated with survival after treatment were further 
characterized using eQTL analysis in two large gene 
expression data sets and subsequent in silico analyses. 
RESULTS
rs6500843 and rs11155012 are associated with 
survival after adjuvant chemotherapy
Initially, a genome-wide study (Stage I: HEBCS-
GWS; n = 805) was conducted to discover candidate SNPs 
that may be associated with breast cancer survival, with 
an emphasis on treatment-based subgroups. This initial 
stage of the analysis was carried out using three different 
endpoints in parallel: five-year BDDM (breast cancer 
death or distant metastasis), 10-year breast cancer specific 
survival, and 10-year overall survival, using a codominant 
genetic model (test for heterogeneity between genotypes). 
We used fairly lenient statistical criteria to select candidate 
SNPs at this stage: a SNP would be selected for validation 
if it fulfilled any of the following criteria: 1) main effect p 
< 10-4 and p < 0.01 among chemotherapy-treated cases, 2) 
p < 10-4 among chemotherapy-treated cases, or 3) p < 10-3 
among chemotherapy-treated cases and a homozygote-
associated hazard ratio > 3.0. In total, we identified 45 
putative hits from this Stage I pilot that were represented 
by 39 nominal and tagging SNPs on the iCOGS chip 
(Supplementary Table 1). 
The candidate SNPs from Stage I were then 
analyzed in Stage II, comprising of the iCOGS, POSH 
and SUCCESS-A data sets. All Stage II survival analyses 
were restricted to cases who had received adjuvant 
chemotherapy. The analyses were run under the additive 
genetic model with left-truncated follow-up times, 
adjusted for patient age at diagnosis, and (in the case of 
iCOGS) stratified by study. Ten-year overall survival 
(death from any cause) was used as the end-point in these 
analyses for reasons of data availability and consistency. 
Three of the SNPs were statistically significant at this 
stage (Benjamini-Hochberg-adjusted p < 0.05): rs6500843 
(any chemotherapy; HR 1.16, 95% C.I. 1.08 - 1.26, p = 
0.0001, p
(adjusted)
 = 0.0091); rs4502225 (any chemotherapy; 
HR 0.78, 95% C.I. 0.67 - 0.90, p = 0.0007, p
(adjusted)
 = 
0.0263); and rs11155012 (anthracycline therapy; HR 1.21, 
95% C.I. 1.08 - 1.35, p = 0.0010, p
(adjusted)
 = 0.0270)(Table 
1). Of these, the calculated hazard ratio for rs4502225 was 
in the opposite direction than in Stage I, and therefore this 
SNP cannot be considered a validated hit.
Finally, we performed a meta-analysis of both the 
Stage I and Stage II data sets, resulting in very slight 
improvement in the precision of the per-allele HR 
estimates for the remaining two SNPs: HR 1.18 (95% 
C.I. 1.10 – 1.27; p = 6.96 × 10-6) for rs6500843 in the 
chemotherapy-treated group, and HR 1.23 (95% C.I. 1.11 – 
1.37; p = 8.41 × 10-5) for rs11155012 in the anthracycline-
treated group. See Figure 1 for forest plots displaying 
hazard ratios from Stage I and Stage II data sets, as well 
as from individual participant studies within the iCOGS 
data set. We detected nominally significant heterogeneity 
(p = 0.048) among the data sets in the rs6500843 analysis, 
indicating some disagreement between data sets; the 
SNP-associated increased hazard was not seen in the 
SUCCESS-A data set. No heterogeneity was observed in 
the case of rs11155012 (p = 0.415). Neither rs6500843 nor 
rs11155012 were associated with tumor histopathological 
characteristics (Supplementary Table 2), nor were the 
survival analyses described above adjusted for patient 
or tumor characteristics except age at diagnosis. More 
detailed phenotypes were taken into account in the 
subsequent interaction analyses (see below).
rs6500843 interacts with adjuvant chemotherapy 
in multivariate survival analysis
Next, we investigated whether the observed survival 
effects are specific to the chemotherapy-treated subgroup, 
and whether these effects occur independently of standard 
prognostic factors. To this end, we tested for interaction 
between treatment and the rs6500843 and rs11155012 
SNP genotypes in multivariate Cox proportional hazards 
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models adjusted for ER, grade, tumor size, and nodal 
metastasis. This analysis was only performed in the iCOGS 
data set, as it contains both treated and non-treated cases 
in abundant numbers, enabling robust interaction testing. 
A likelihood-ratio test comparing models with interaction 
terms with models with only independent covariates 
indicated an interactive effect between rs6500843 and 
adjuvant chemotherapy (p
(interaction)
 = 0.0009, N = 9680 
[1176 events]; Table 2), consistent with the finding 
that the SNP was associated with survival in the “any 
chemotherapy” subset in univariate analysis. See Figure 
2 for a visualization of rs6500843-associated survival 
within the chemotherapy-treated and untreated subgroups 
in the iCOGS data set. Consistent with the additive model 
employed in the survival analyses, the genotype-specific 
hazard ratios for rs6500843 in the chemotherapy-treated 
group increase in an allele dose dependent manner (HR
(AG)
 
= 1.22 (95% C.I. 1.00 - 1.49); HR
(GG)
 = 1.47 (95% C.I. 1.20 
- 1.80). In contrast, no heterogeneity between genotypes 
can be observed in the untreated group. The conclusion of 
the interaction analysis did not change when radiotherapy, 
surgery, and adjuvant endocrine therapy were added as 
additional covariates in the model (p
(interaction)
 = 0.0035, N = 
8943 [1110 events]). Despite its association with survival 
in the anthracycline-treated and any chemotherapy treated 
subsets, no evidence of interaction was observed for the 
rs11155012 SNP (Supplementary Table 3), suggesting 
that its possible association with survival is not entirely 
treatment-specific.
eQTL analysis of SNPs in the survival-associated 
loci
To determine if rs6500483 or rs11155012, or other 
SNPs in the surrounding LD regions (r2 > 0.1), associate 
with gene expression in breast cancer, two publicly 
available data sets (containing both genotype and gene 
expression data) were used for expression quantitative 
loci (eQTL) analysis: TCGA [12], and METABRIC [13]. 
We classified eQTLs as cis if they occurred within ±1 Mb 
from any SNP in the LD region; any eQTLs outside these 
regions were classified as trans. 
The SNP rs6500843 is located in chromosome 
16, in an intron of the RBFOX1 gene, which is the 
Table 1: Survival statistics for the three SNPs associated with 10-year overall survival in 
the Stage II analysis.
rs6500843 rs4502225 rs11155012
Chromosome 16 16 6
Position 6 870 855 78 424 831 139 151 784
Genes in LD region RBFOX1 WWOX ECT2L, CCDC28A
Subgroup Chemotherapy+ Chemotherapy+ Anthracycline+
Model additive additive additive
Stage I (HEBCS-GWS)
p-value 0.0081 0.0045 0.0073
HR 1.36 1.55 1.50
95% C.I. 1.08-1.70 1.14-2.09 1.12-2.02
Stage II (iCOGS, POSH, SUCCESS-A)
p-value 0.0001 0.0007 0.0010
(Adjusted)* 0.0091 0.0263 0.0270
HR 1.16 0.78 1.21
95% C.I. 1.08-1.26 0.67-0.90 1.08-1.35
Meta-analysis (Stage I, Stage II)
p-value 6.96 × 10-6 0.0594 8.41 × 10-5
HR 1.18 0.88 1.23
95% C.I. 1.10-1.27 0.77-1.01 1.11-1.37
* Benjamini-Hochberg correction for multiple testing
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only gene in the immediate LD region surrounding 
the SNP. The expanded cis-eQTL region (±1 Mb) 
surrounding the SNP also contains the RNA coding 
genes MIR8065, LINC01570, and LOC102723308, as 
well as the uncharacterized gene LOC440337. No cis-
eQTLs were observed in the rs6500843 locus. When 
we examined trans-eQTLs, the expression levels of six 
genes were associated with genotypes in the rs6500843 
locus; MCM3, CENPM, PKMYT1, AURKA, KIFC1, 
TK1 (Bonferroni-corrected for all genes on the array; p 
< 0.05). In an enrichment analysis for Gene Ontology 
biological processes, using an arbitrary raw eQTL p-value 
threshold of p < 10-5 to select an expanded candidate gene 
list, GO terms involved in cell cycle control, mitosis and 
DNA replication emerged as highly significant for the 
trans-eQTLs (34 probes representing 28 genes) in the 
rs6500843 locus (Table 3). Note that rs6500843 itself was 
not present in the data set, nor were any SNPs in complete 
LD with it. The vast majority of eQTLs in this region are 
associated with the SNPs rs6500842 (r2 0.54, D’ 0.87 with 
rs6500843) and rs7205424 (r2 0.26, D’ 0.53), suggesting 
a biologically significant role for the haplotype(s) tagged 
by these two SNPs. 
The LD region around rs11155012 contains two 
genes: CCDC28A and ECT2L. In total, 34 genes are 
located in the expanded cis-eQTL region around this 
locus. One nominally significant cis-eQTL was observed 
in this region, and occurred as a positive correlation 
between the rare allele of rs9321678 (r2 = 0.147, D’ = 1 
with rs11155012) and the neighboring CCDC28A gene 
(t = 2.003, p = 0.0454). In the trans-eQTL analysis, the 
rs11155012 locus was associated with the expression of 
the genes CHRFAM7A, CRYBB2, RASGRP4, MOCS1, 
SOX21, and UPK3B. No statistically significant GO term 
enrichment was detected for the rs11155012 locus.
The complete trans-eQTL results for both loci are 
presented in detail in Supplementary Table 4. 
Figure 1: Forest plots depicting study-wise hazard ratios for the statistically significant SNPs detected in Stage II. a) 
Hazard ratios for rs6500843 among cases treated with any adjuvant chemotherapy (additive model); b) Hazard ratios for rs11155012 among 
anthracycline-treated cases (additive model).
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Expression based survival analysis of the genes 
associated with the rs6500483 and rs11155012 loci
Next, we utilized the Kaplan-Meier Plotter database 
[14] to investigate whether any of the genes surrounding 
our statistically significant SNPs are associated with breast 
cancer survival (10 year relapse-free survival) at the gene 
expression level. Regions of interest were defined as 
regions containing SNPs with r2> 0.2 to the nominal SNP. 
The region for rs11155012 contained two genes (ECT2L, 
CCDC28A), and the region for rs6500483 contained 
one (RBFOX1/A2BP1). These candidate genes were 
analyzed in the “any adjuvant chemotherapy” category, 
as information on specific types of chemotherapy was not 
available in the database. Among these cases (N = 425), 
high expression of the gene CCDC28A was associated 
with better prognosis (p = 0.00012, HR 0.5, 95% C.I. 0.35 
- 0.72) (Supplementary Figure 1). It was also associated 
with prognosis in the full data set, irrespective of treatment 
(N = 3455, p = 0, HR 0.56, 95% C.I. 0.49 - 0.63). This is 
consistent with the results of the cis-eQTL analysis: the 
rare allele of rs9321678 was associated with increased 
CCDC28A expression, which in turn is associated with 
better prognosis. The rare alleles of rs11155012 and 
rs9321678 segregate in different haplotypes (negative 
correlation), as can be deduced from the LD information 
(r2 = 0.147, D’ = 1, MAFs are roughly equal [0.20 and 0.18, 
respectively]). Consequently, the rare allele of rs11155012 
would be expected to associate with worse prognosis, 
which is indeed the case in our SNP survival analysis. 
Of the trans-eQTL genes associated with the rs11155012 
locus, the genes CHRFAM7A, CRYBB2, MOCS1 and 
SOX21 were associated with survival among all cases in 
the KM-Plotter analysis, whereas only one (SOX21) was 
associated with survival among chemotherapy-treated 
cases (Supplementary Table 5). Significant heterogeneity 
(p = 0.0044; 0.0239 after BH-adjustment for multiple 
testing) was observed for SOX21: high SOX21 associated 
with better prognosis among untreated cases (HR 0.82, 
95% C.I. 0.69 – 0.98), but the effect was reversed among 
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chemotherapy-treated cases (HR 1.45, 95% C.I. 1.02 – 
2.06).
Expression of the RBFOX1 gene at the rs6500483 
locus did not associate with survival in the KM-plotter 
database, either among chemotherapy-treated cases or 
among all cases. In contrast, all six trans-eQTL genes 
associated with the rs6500843 locus (MCM3, CENPM, 
PKMYT1, AURKA, KIFC1, TK1) were associated with 
survival when analyzing all cases irrespective of treatment, 
as well as among cases who specifically had not received 
systemic chemotherapy. All other genes but AURKA 
associated also with survival among cases treated with 
adjuvant chemotherapy (Supplementary Table 5) which 
would suggest a treatment-independent effect for most 
of these genes. However, a test of heterogeneity between 
the treated and non-treated groups indicated a statistically 
significant difference in AURKA-associated survival 
between treated and non-treated cases (heterogeneity 
Oncotarget7397www.impactjournals.com/oncotarget
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p=0.021 after BH-adjustment for multiple testing): while 
high AURKA expression associated with poor survival in 
untreated cases, no such effect was seen in chemotherapy-
treated cases. 
Next, we investigated the possible connection 
between the rs6500843 locus and the trans-eQTL genes. 
Rs6500843 is located in an intron of RBFOX1, a tissue-
specific splicing regulator, for which target genes have 
been previously published [15]. Given that the genetic 
neighborhood around rs6500843 contains no other protein 
coding genes, and little is known about the three RNA 
coding genes in the region, we operated here under the 
hypothesis that the SNP is functionally associated with the 
RBFOX1 gene. As splice variants of gene products may 
give rise to different signals in microarray experiments, 
we cross-referenced the published list of RBFOX1 
targets against our expanded list of putative trans-eQTL 
genes (raw p < 10-5 in the eQTL analysis) that also fall 
within the enriched GO:0007049 (cell cycle) Gene 
Ontology group (Table 3), and came up with one gene: 
the transcription factor FOXM1. Genome-wide target 
genes for FOXM1 have also been previously published 
[16]; comparison of the statistically significant sites 
(combined genomic binding and coexpression) with our 
trans-eQTL list yielded four genes regulated by FOXM1: 
EXO1, MCM6, UHRF1, and KPNA2. These connections 
between the genomic locus and the eQTL genes have been 
schematically summarized in Figure 3.
The rs11155012 locus contains a genomic 
regulatory region
Finally, we investigated the possibility that the 
prognostic SNPs identified in this study are in linkage 
disequilibrium with other, functionally significant 
variants in their genomic vicinity. All SNPs in linkage 
disequilibrium (r2> 0.2) with rs6500843 and rs11155012 
were analyzed using HaploReg, a database of genomic 
regulatory elements [17]. Rs11155012 is in high LD 
with a number of SNPs affecting a genomic enhancer 
Figure 2: Kaplan-Meier curves illustrating cumulative 10-year overall survival among cases of the pooled iCOGS data 
set categorized by rs6500843 genotype. The HRs indicate genotype-specific hazard ratios relative to the reference genotype (AA). 
Censoring marks have been omitted to make the curves clearer. The data set has been subgrouped according to treatment: a) patients treated 
with any adjuvant chemotherapy, b) patients who did not receive adjuvant chemotherapy.
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site (Supplementary Table 6) active in human mammary 
epithelial cells (HMEC). The site has been experimentally 
shown to bind the proteins FOXA1 and FOXA2, and 
a Foxa binding motif is predicted to be altered by 
rs6570291, a SNP in near-complete LD with rs11155012 
(r2 = 0.99).
Equally strong evidence of an active regulatory site 
was not observed for the rs6500843 locus. The SNP itself 
is predicted to alter 33 transcription factor binding motifs, 
mostly homeobox-containing tissue-specific transcription 
factors, but no supporting experimental evidence is present 
in the HaploReg data.
DISCUSSION
We have utilized three independent data sets 
to evaluate the significance of putative prognostic/
predictive SNPs from an initial GWS pilot investigating 
survival after adjuvant chemotherapy in breast cancer. 
This analysis was carried out as a meta-analysis between 
iCOGS studies and two additional data sets (SUCCESS-A, 
POSH). Two loci emerged as statistically significant in the 
two-stage analysis: rs6500843 among cases treated with 
any chemotherapy, and rs11155012 among cases treated 
with anthracyclines. Of these, rs6500843 was found to 
interact with adjuvant chemotherapy in a subsequent 
multivariate interaction analysis, reinforcing the notion 
that its association with survival may have a predictive 
basis: carriers of the rs6500843 G-allele appear to have 
somewhat worse survival than other chemotherapy-treated 
cases.
The only gene in the LD region surrounding 
rs6500843 is RBFOX1 (A2BP1), which encodes a highly 
conserved RNA-binding protein involved in the control of 
tissue-specific mRNA splicing [18]. It has been identified 
as a common target of LOH and copy number variation in 
other types of malignancies [19-21], and a SNP in the gene 
(not in LD with rs6500843) has been reported to associate 
with survival in non-small-cell lung cancer [22], but little is 
known about its role in breast cancer. While the rs6500843 
SNP is predicted to alter a homeobox transcription factor 
binding site targeted by 33 transcription factors, we did 
not find further experimentally verified evidence of a 
genetically modulated regulatory region in this locus, nor 
was RBFOX1 gene expression itself associated with breast 
cancer survival. However, a trans-eQTL analysis of the 
Figure 3: Schematic summary of the putative evidence connecting the rs6500843 SNP to the trans-eQTL SNPs 
associated with this locus. The eQTL genes marked in bold are associated with the rs6500843 locus at a statistically significant level 
after conservative Bonferroni correction; the remaining genes listed here are associated with SNP genotype at p < 10-5, and also belong to 
the Gene Ontology group GO:0007049 (cell cycle) which was most strongly enriched in the DAVID analysis. RBFOX1 and FOXM1 target 
gene identification is based on previously published data [13, 14].
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SNPs in the rs6500843 region identified six statistically 
significant genes, all of which were associated with 
survival in breast cancer in the Kaplan-Meier Plotter 
analysis (and five in the chemotherapy-only subgroup). 
Notably, the Aurora-A kinase (AURKA) associated with 
differential survival when comparing chemoterapy-treated 
and non-treated cases. High AURKA expression appeared 
to associate with poor survival in untreated cases, whereas 
no such effect was seen in chemotherapy-treated cases, 
which suggests a favorable response to the chemotherapy 
regimens administered to these cases. AURKA has been 
previously suggested to be a master regulator of cellular 
radio- and chemoresistance, proliferation, cell cycle 
progression and anchorage-independent growth [23]. 
In order to detect enriched Gene Ontology 
biological processes among the eQTL genes, we relaxed 
the criteria of statistical significance and analyzed a 
slightly larger list of candidate genes (n = 28). This set 
of candidates was strongly enriched for genes involved 
in cell cycle control (GO: 0007049; cell cycle): 15 
out of 28 genes fell within this category, an 11-fold 
enrichment compared to a random selection of genes. 
The set of genes includes EXO1, knockdown of which 
has been reported to desensitize H196 lung cancer cells 
to paclitaxel treatment [24]; KIFC1, reported to modulate 
docetaxel sensitivity [25]; the breast cancer susceptibility 
gene CHEK2 [26, 27]; the Bloom syndrome gene BLM 
[28]; and the Survivin gene BIRC5, reported to associate 
with chemo- and radioresistance in breast cancer [29]. It 
is intriguing to see this group of cell cycle control and 
chemoresistance-associated genes emerge in eQTL with 
a SNP associated with survival after chemotherapy, 
especially as there is a plausible connection between the 
rs6500843 locus and this set of trans-eQTL genes (Figure 
3). Rs6500843 is located in an intron of RBFOX1, a 
tissue-specific splicing regulator that targets the proto-
oncogene FOXM1, a transcription factor involved in cell 
cycle control. In our analyses, FOXM1 itself emerged as a 
putative trans-eQTL gene associated with the rs6500843 
locus, and it has been reported to regulate four other 
genes on that list: EXO1, MCM6, UHRF1, and KPNA2. 
Of these, EXO1 is of particular interest, as the FOXM1-
EXO1 regulatory connection has been previously reported 
to modulate chemoresistance in ovarian carcinoma cells 
[30]. An important caveat to this analysis is that the SNP 
rs6500843 itself was not present in the eQTL data set, 
and the eQTL results are based on SNPs in incomplete 
linkage disequilibrium with it. The functional significance 
of rs6500843 itself, and the putative transcription factor 
binding site it resides in, therefore remains unclear. 
The other SNP emerging as statistically significant 
in the validation analysis, rs11155012, is located in a LD 
region that contains two genes, CCDC28A and ECT2L, the 
biological functions of which are poorly understood. Our 
analysis of publicly available gene expression data [12] 
indicates that CCDC28A transcript abundance is associated 
with relapse-free survival in breast cancer, which suggests 
that rs11155012 may be linked to a prognostically 
significant functional variant in this gene. Indeed, 
rs11155012 is in LD with a number of SNPs affecting 
a genomic enhancer site active in human mammary 
epithelial cells. The site has been experimentally shown to 
bind the proteins FOXA1 and FOXA2, and a Foxa binding 
motif is predicted to be altered by rs6570291, a SNP in 
near-complete LD with rs11155012 (r2 = 0.99). FOXA1 
(Hnf-3-alpha) is a key transcription factor involved in 
mechanisms known to be critical in breast carcinogenesis: 
estrogen receptor -mediated signaling, and cell cycle 
control in conjunction with BRCA1 [31, 32]. Furthermore, 
a modest cis-eQTL effect was observed between 
rs9321678 (r2 = 0.147, D’ = 1 with rs11155012) and the 
CCDC28A gene. We also detected a trans-eQTL between 
rs9495127 (r2 = 0.129, D’ = 1) and the transcription 
factor SOX21, a gene whose expression associates with 
increasing hazard among chemotherapy-treated cases 
despite being protective in untreated cases. While causality 
cannot be established without experimental work, these 
findings provide supporting evidence for an association 
between genetic variation in this regulatory site and breast 
cancer survival. The predictive value of this genetic locus 
remains questionable, however, as we did not observe 
an interaction between rs11155012 and treatment in the 
clinical data.
The hazard ratios for rs6500483 show some 
heterogeneity between the data sets used in this study: 
SUCCESS-A appears to disagree with the other data sets. 
Rs6500483 is represented in SUCCESS-A by rs4786939, 
but these two SNPs are in nearly complete linkage 
disequilibrium (r2 0.967, D’ 1.0), indicating that the use of 
a tagging SNP is an unlikely source of heterogeneity here. 
Heterogeneity between follow-up times and treatment 
regimens would be a more likely reason: the cases in 
SUCCESS-A have all received taxane-based therapy, 
a regimen poorly represented in the other data sets. 
Unfortunately, the specific chemotherapy agents involved 
in the genetic association cannot be resolved using our 
currently available data. Additionally, in light of our use 
of GWAS as a starting point, it must be noted that our 
findings do not reach genome-wide significance. However, 
the purpose of the initial Stage I GWAS was to define a 
candidate SNP set that would most likely capture any true 
survival-associated SNPs, the statistical significance of 
which would then be evaluated in the substantially more 
powerful Stage II analysis. We do not anticipate very 
large effect sizes in SNP-based survival analyses, and 
therefore utilized a stepwise study design to alleviate the 
problem of multiple testing and resultant loss of statistical 
power. Only 39 SNPs were analyzed in Stage II, two of 
which meet our criteria of statistical significance. Both 
findings are supported by additional lines of evidence 
from gene expression- and regulome-based analyses. 
Nevertheless, these results must be viewed as exploratory 
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and hypothesis-generating in nature.
In conclusion, we have conducted a two-stage 
genetic association study to detect SNPs associated with 
survival after chemotherapy. One SNP, rs6500843, was 
found to interact specifically with adjuvant chemotherapy, 
independently of standard prognostic markers, whereas 
rs11155012 may associate with survival in general. 
eQTL analysis of the rs6500843 locus identified a group 
of genes known to associate with cancer progression, 
chemoresistance, and survival. We propose that these 
genes may be connected to the rs6500843 locus via a 
RBFOX1-FOXM1 -mediated regulatory pathway. If 
confirmed, these findings may aid in the development of 
better predictive markers and improved individualized 
cancer therapy.
MATERIALS AND METHODS
Study design
Initially, a genome-wide study (Stage I: HEBCS-
GWS) was conducted to discover candidate SNPs that 
may be associated with breast cancer survival, with an 
emphasis on treatment-based subgroups. This candidate 
SNP set was then analyzed in three validation datasets 
(Stage II: iCOGS, SUCCESS-A, POSH). SNPs emerging 
as statistically significant within Stage II were further 
examined in an eQTL analysis of two breast cancer 
data sets (TCGA, METABRIC), supported by in silico 
genomic feature analysis. The data sets used in this study 
are described below, and summarized in Table 4. Informed 
consent has been obtained from all patients included in 
this study.
Discovery GWS (Stage I: HEBCS-GWS)
Genotype information was obtained from a study 
series consisting of 805 Finnish breast cancer cases 
(HEBCS-GWS). All cases were female, ascertained for 
their first primary invasive breast cancer. Of these, 423 
cases originated from a prospective patient series of 
consecutive unselected, incident breast cancer patients 
treated in the Helsinki University Hospital Department 
of Oncology in years 1997–1998 and 2000 [33, 34]. The 
series also includes 140 cases recruited between 2001 and 
2004, and 242 additional familial cases [7, 35]. To increase 
the statistical power of survival analyses, the GWS series 
was specifically enriched for cases with reduced survival 
(distant metastasis or death at the time of the initiation 
of the study in 2008): in total, the series includes 312 
breast cancer specific events, and 339 any-cause mortality 
events at the time of analysis. The cancer diagnoses 
were confirmed through the Finnish Cancer Registry and 
hospital records. Information on the date and cause of 
death was obtained from the Finnish Cancer Registry, a 
central database of diagnostic and death information on all 
cancer patients in Finland.
The HEBCS-GWS series (“Stage I”) was genotyped 
using the Illumina 550K platform as previously described 
[36]. The preliminary survival analysis was carried out 
using three different endpoints in parallel: five-year 
BDDM (breast cancer death or distant metastasis), 10-
year breast cancer specific survival, and 10-year overall 
survival, using a codominant genetic model (test for 
heterogeneity between genotypes). Since survival after 
chemotherapy was the main focus of this study, it would 
have been ideal to entirely restrict the initial Stage I 
analysis only to chemotherapy-treated cases (comprising 
45% of the data set; Table 4), given sufficient statistical 
power. To determine the feasibility of this approach, 
the R package ‘survSNP’ was employed to estimate the 
statistical power of our survival analysis [37]. Using a 
significance threshold of p < 10-5 and a hypothetical SNP 
with a minor allele frequency of 0.25 as the ad hoc target 
for discovery, we had 80% power to detect a per-allele HR 
of 1.6 in the whole sample set, but only 32% power if the 
analysis was restricted to chemotherapy-treated cases only. 
Analysis of specific chemotherapy regimens would have 
decreased the statistical power further. Based on this, we 
concluded that a treatment-based subgroup analysis alone 
would be unacceptably underpowered. Therefore, to be 
eligible for subsequent validation, SNPs had to meet one 
of these three more inclusive criteria: 1) main effect p < 
10-4 and p < 0.01 among chemotherapy-treated cases, 2) p 
< 10-4 among chemotherapy-treated cases, or 3) p < 10-3 
among chemotherapy-treated cases and a homozygote-
associated hazard ratio > 3.0. These SNPs (n = 45) were 
then selected as candidates for Stage II validation and 
genotyping as part of the iCOGS project [2].
Validation studies (Stage II: iCOGS, POSH, 
SUCCESS-A)
The candidate SNPs from Stage I were analyzed in 
three additional data sets: iCOGS, POSH, SUCCESS-A 
(described in detail below). 
iCOGS
SNPs identified as putatively significant in Stage 
I HEBCS GWAS analysis of chemotherapy-treated 
cases were included on a custom Illumina Infinium 
array (iCOGS) for large scale genotyping of a data set 
of 50927 individuals from 52 Breast Cancer Association 
Consortium (BCAC) member studies, 41 of which were 
of predominantly European ancestry, 9 of Asian, and 2 
of African-American ancestry. Genotyping and quality 
control was carried out as previously described [2].
Studies represented on the iCOGS chip were 
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included in survival analysis here if sufficient follow-
up data was available, with a minimum requirement of 
at least 10 survival events (deaths from any cause) per 
study. Additionally, we included only studies with cases 
from predominantly European ancestry, and from which 
adjuvant chemotherapy information was available. At the 
individual level, we included only female cases ascertained 
for their first primary, invasive tumor. After these filtering 
steps, the data set consisted of 17828 eligible cases (2198 
any-cause deaths; 12%), of which 6720 cases were treated 
with any adjuvant chemotherapy. Of these, 3010 cases 
were known to have been treated with anthracycline-
based chemotherapy. While data on taxane (n = 868) 
and methotrexate-based (n = 1022) adjuvant treatment 
was also available, these treatments were not analyzed 
as separate subgroups due to the small sample sizes and 
poor comparability with the other data sets (Table 4). For 
2528 cases, the specific type of chemotherapy regimen 
was unknown. The cases included here come from 16 
separate BCAC studies, which have been described in 
Supplementary Table 7.
POSH GWS
The POSH GWS consisted of 536 individuals (236 
any-cause deaths; 44%) selected from a consecutively 
ascertained cohort of early onset cases (diagnosed with 
invasive breast cancer at the age of 40 or earlier) from 
the United Kingdom. These cases were enrolled into 
the Prospective study of Outcomes in Sporadic versus 
Hereditary breast cancer (POSH) between 2000 and 2008, 
as previously described [38]. The POSH GWS material 
was enriched for cases with poor prognosis by including 
cases with triple-negative breast cancer (n=401), and 
cases with particularly short duration of breast cancer 
survival (<2 years, n=48); additional cases with relatively 
long survival were then included for contrast (>4 years, 
n=125) [39]. These cases were genotyped on the Illumina 
660-Quad SNP array; genotyping and quality control was 
carried out as previously described [39]. 518 cases (97%) 
in this data set were treated with adjuvant chemotherapy.
SUCCESS-A
SUCCESS-A is a randomized Phase III study of 
response to treatment of early primary breast cancer with 
adjuvant therapy after surgical resection. The cases are 
all treated with anthracycline- and taxane-based adjuvant 
chemotherapy, and randomized for Gemcitabine treatment. 
The sample set consisted of 3596 cases (207 any-cause 
deaths; 6%) that were recruited between 2005 and 2007 
from 250 study sites across Germany. Genotyping was 
carried out using the Illumina Human OmniExpress-
FFPE BeadChip platform. The SUCCESS-A data as well 
as detailed descriptions of the materials and methodology 
can be acquired from the NCBI database of Genotypes 
and Phenotypes (dbGaP Study Accession: phs000547.
v1.p) [40].
Statistical analysis
In stage II, unless otherwise noted, 10-year overall 
survival (death from any cause) was used as the end point 
in all survival analyses, as all-cause mortality data was the 
most widely available in the iCOGS data set. This also 
allowed us to avoid the potential biases that can arise from 
clinical follow-up data in multicenter studies [41]. 
All survival analyses were run under the additive 
genetic model, follow-up times left-truncated, and 
adjusted for patient age at diagnosis, and (in the case of 
iCOGS) stratified by study in order to minimize potential 
biases arising from differing case recruitment strategies 
and different populations of origin. The analyses were 
performed within the same subgroups (chemotherapy-
treated cases and anthracycline-specific analysis) as in 
stage I. 
To alleviate potential biases arising from population 
stratification, e.g. cryptic relatedness of cases, the analysis 
was also adjusted for three genetic principal components 
to correct for possible population substructure. The 
principal components were calculated from the genotypes 
of uncorrelated (r2 < 0.2) SNPs in the genome-wide 
data sets. Briefly, for the HEBCS-GWS, POSH and 
SUCCESS-A data sets, we pruned a subset of SNPs not 
in substantial LD with any other SNPs (r2< 0.2) and ran a 
principal component analysis (PCA) using the ‘GenABEL’ 
package in R. The PCA analysis for iCOGS has been 
described previously [2]; as with the other three data sets, 
only three principal components were used in this study.
The selected SNPs from the HEBCS-GWS data 
set (Stage I) were also re-analyzed at this point using the 
same parameters as with the validation data. This means 
that Stage I results were here re-analyzed only under the 
additive model (which can be expected to capture both 
dominant and recessive signals), regardless of the original 
selection criteria, reducing the amount of multiple testing 
in the final meta-analysis stage. While the original SNP 
selection was based on more inclusive criteria, the 
purpose of this was to ensure that the final results are 
directly comparable across the stages of the study. Thus, 
allele calling and quality control for HEBCS-GWS was 
performed as previously described [39], and the survival 
analysis was performed as described above. Similar to the 
validation data sets, principal component analysis (PCA) 
was included for HEBCS-GWS as well at this stage.
Results of the Stage II (iCOGS, POSH, 
SUCCESS-A) survival analysis were meta-analyzed 
under a fixed-effects model using the ‘rmeta’ package in 
R, and the resulting meta-statistics were used to determine 
statistical significance. Benjamini-Hochberg correction 
was applied to account for multiple testing [42].
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Statistically significant SNPs in treatment-based 
subgroups were further tested for interaction with 
treatment in the iCOGS data set, as it contains both treated 
and non-treated cases in abundant numbers, enabling 
robust interaction testing. This analysis was adjusted 
for clinically relevant covariates (grade, ER, tumor 
size category [T], nodal status [N], age at diagnosis). 
Distant metastasis at diagnosis (M) was not included 
as a covariate, as this information was missing for the 
majority of cases. To avoid biases introduced by mostly 
missing data, cases known to be M1 were not specifically 
excluded from the analysis either. Two Cox proportional 
hazards models were generated, one with the SNP and 
treatment status as independent covariates, and one that 
also included an interaction term between genotype and 
treatment. The statistical significance of an interaction 
was then determined using a likelihood-ratio test between 
the two models. To rule out confounding effects caused 
by other treatment types, we also conducted a secondary 
interaction analysis where radiotherapy (yes/no), surgery 
(yes/no), and adjuvant endocrine therapy (yes/no) were 
added as additional covariates in the model.
We employed chi-square tests of heterogeneity 
to test for association between SNP genotypes and the 
following clinicopathological characteristics: estrogen 
receptor status (ER; positive or negative), histological 
grade (1 – 3), tumor size (T; 1 – 4), and lymph node 
metastasis (N; positive or negative) in the iCOGS data set. 
eQTL analysis
To determine if the survival-associated SNPs or 
other SNPs in the LD region (r2 > 0.1) associate with 
gene expression in breast cancer, two publicly available 
data sets (containing both genotype and gene expression 
data) were used for eQTL analysis: TCGA [12], and 
METABRIC [13]. The TCGA gene expression data is 
mRNA sequencing data from the Illumina HiSeq 2000 
platform, whereas the METABRIC gene expression data 
was generated by the Illumina Human WG6 v3 platform. 
Tumor tissue genotyping had been carried out using the 
Affymetrix Genome Wide Human SNP array 6.0 for 
both data sets. Of the two validated SNPs, rs11155012 
itself was represented on this SNP array, whereas 
rs6500843 was not. The latter was best represented by 
the linked SNPs rs4786121 and rs7190693 (r2 0.603, D’ 
1.0 for both SNPs); note that all SNPs in the LD region 
with r2 > 0.2 were nevertheless included in the eQTL 
analysis. The TCGA breast cancer data set consists of 
913 solid breast tumor samples that also had genotype 
data available. METABRIC consists of 1328 solid breast 
tumor samples with both genotype and gene expression 
data. eQTL analysis was carried out by calculating linear 
models between genotype and gene expression using the 
R package ‘MatrixEQTL’ [43]. Only genes present in 
both data sets were included in the analysis: the TCGA 
and METABRIC data sets were analyzed separately and 
then meta-analyzed to detect the most consistent results. 
We searched for cis-eQTLs within regions defined as ±1 
Mb from any SNP in the LD region; no formal multiple 
testing correction was applied to eQTL results within these 
regions. Any genes outside these regions were analyzed 
for trans-eQTL and subjected to transcriptome-wide 
multiple testing correction (Bonferroni).
In addition to looking for individual genes that are 
statistically significant in the eQTL analysis, we also ran a 
pathway-enrichment analysis on a set of candidate genes 
selected using a more lenient p-value threshold from the 
eQTL analysis (raw p < 10-5). The analysis was restricted 
to Gene Ontology Biological Processes and was performed 
using the DAVID Functional Annotation Tool [44, 45].
Further in silico evaluation of SNPs and candidate 
genes
It is likely that the prognostic SNPs identified in this 
study are merely linkage disequilibrium proxies for other, 
functionally significant variants in their genomic vicinity. 
In an effort to identify the SNPs and genes with a direct 
functional impact on breast cancer survival, we utilized a 
number of public databases. For these analyses, regions 
of interest were defined as regions containing SNPs in 
linkage disequilibrium with the survival-associated SNPs 
at r2> 0.1. Candidate genes in the regions surrounding the 
prognostic SNPs, as well as statistically significant trans-
eQTL genes associated with the survival-associated loci, 
were analyzed in the Kaplan-Meier plotter (http://kmplot.
com/analysis/), a gene expression and survival database 
currently consisting of 4142 breast cancer cases, of which 
425 were known to have been treated with adjuvant 
chemotherapy [12]. These analyses were performed using 
10-year relapse-free survival, as this was the only end 
point available for the majority of cases in the Kaplan-
Meier plotter data set, and optimized break points for 
the binarization of gene expression levels. All SNPs 
in these regions were further analyzed for their impact 
on regulatory features using HaploReg, a database of 
genomic functional annotations [15]. 
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